ACT Genomics is proud to have 4 abstracts accepted for publication at 2018 ASCO! The abstracts highlight our experiences in identifying actionable alterations across different solid tumors using comprehensive genomic profiling, as well as experiences in utilizing hot-spot panel to guide lung cancer therapy.
- Clinical targeted next-generation sequencing to identify potentially actionable alterations in the majority of Asian cancer patients.
- Application of a cancer hot-spot panel to guide lung cancer therapy: Asian experience.
- Reliable diagnosis of BRCA1/2 germline mutations from tumor testing using a next-generation sequencing (NGS) platform.
- Comprehensive genomic profiling of colorectal cancers with and without microsatellite instability (MSI) and elevated microsatellite alterations at selected tetranucleotide repeats (EMAST).